| Chinese traditional patent; sample number (n) | Ingredients | Control; sample number (n) | Total clinical effect rate | Model used | Therapeutic effects and actions | Refs. |
| Guizhi Fuling capsules (GFC); n = 93 | Gui Zhi, Fu Ling, Mu Dan Pi, Tao Ren, Bai Shao | Gestrinone; n = 94 | | Human study | CA-125↓, CA-199↓ | [52] | ELeng capsules (ELC); n = 25 | San Leng, E Zhu, Dan Shen, Yu Jin, Bie Jia, Chi Shao, Ji Nei Jin, Zhe Bei Mu | Nemestran; n = 25 | D: 84.00% -48% vs. 80%-36% | Human study | Alleviate dysmenorrhea CA-125↓, PRL↓ | [57] | Dan Bie capsules (DBC) | Dang Shen, San Qi, San Leng, Tao Ren, Dang Gui, Bie Jia, Hai Zao, Du Zhong, Bai Zhu, Ban Zhi Lian, Gui Zhi | GFC | | SD rat model | PGF2α↓, PGE2↓ | [58, 59] | Sanjie analgesic capsules (SAC); n = 112 | Long Xue Jue, San Qi, Zhe Bei Mu, Yi Yi Ren | Danazol; n = 46 | T: 92.9% vs. 77.5% | Human study | Alleviate dysmenorrhea Shrink endometrioic lesion Recurrence rate↓ | [63] | Dane Fukang paste (DFP); n = 75 | Dan Shen, E Zhu, Chai Hu, San Qi, Chi Shao, Dang Gui, San Leng, Xiang Fu, Yuan Hu, Gan Cao | Gestrinone; n = 75 | T: 95.45% vs. 81.82% | Human study | Alleviate dysmenorrhea | [66] |
|
|